A Phase 2 interventional study of Givinostat in Polyarticular Course Juvenile Idiopathic Arthritis, sponsored by Italfarmaco. Terminated at 13 sites in 7 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-04-16.
Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Arthritis, Juvenile with a site in Italy — 20 open to participants now, 24 under way, 11 of them phase 3. Arthritis, Juvenile · Italy.
Among the 56 studies in Arthritis, Juvenile with a site in Italy, this one is the 42nd largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2010, is one of 5 in phase 2, and was the 12th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →20 of the 56 studies in Arthritis, Juvenile with a site in Italy are open now. Recruiting first, the newest first:
Alfasigma S.p.A. · Sites in Italy, Belgium, Czechia and 6 more countries
Ages 8–18
Duke University · Sites in Italy, United States, Germany and 1 more country
Ages 2–21
Novartis Pharmaceuticals · Sites in Italy, United States, Canada and 5 more countries
Ages 1+
Bristol-Myers Squibb · Sites in Italy, United States, Brazil and 8 more countries
Ages 5–17
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 6–18
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 28 · Phase 4 2
First in 2000; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 90 across the 43 interventional studies, 130 across the 13 observational. Of the 30 that completed or were terminated, 20 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 56 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 3 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Juvenile with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT06618937Istituto Giannina GasliniToward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission | 2027-01-01 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Arthritis, Juvenile with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study has been designed in order to evaluate the efficacy and safety of two doses of Givinostat in subjects with polyarticular course JIA
Givinostat ready-to-use suspension especially intended for paediatric administration, will be administered orally at different daily doses.
Patients with an established diagnosis of one of the following JIA forms (Polyarticular JIA rheumatoid factor positive or negative, Oligoarticular extended JIA, Systemic JIA without active systemic features) will be enrolled.
The treatment regimen will remain unchanged for 12 weeks and the clinical response will by assessed by applying the ACR Pediatric response criteria. Patients achieving at least an ACR Pediatric 30 response will continue receiving the assigned dose for 12 further weeks.
After the end of study (week 24) responder patients will be allowed to extend the treatment until they maintain a clinical benefit.
Non-clinical data on Givinostat, support a potent anti-inflammatory mechanism of action which can potentially slow the arthritic destructive process. This rationale seems to be confirmed by the preliminary evidences collected in a previous Phase II clinical trial conducted in children and young adults with systemic JIA.
The present protocol is aimed at collecting new information on safety and efficacy of two doses of Givinostat for the treatment of JIA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Givinostat
Drug: Givinostat
1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
ACR Pediatric Response Level (ACRPRL) 30 After 12 Weeks of Treatment
ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0-100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 30 of response, defined as a 30% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%
Time frame: 12 weeks of treatment
ACR Pediatric Response Level (ACR 50, 70, 90 and 100) at Week 12
ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0- 100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 50, 70, 90 and 100 of response, defined as a 50%, 70%, 90% and 100% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%
Time frame: at week12
Recruitment period: October 2010 - December 2011. The study was conducted by nine Investigators in five countries across Europe; three Investigators in Italy, two Investigators each in Romania and Serbia, and one Investigator each in Czech Republic and Slovenia
| Milestone | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg Twice Daily (BID) | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID |
|---|---|---|
| Started | 10 | 6 |
| Completed | 9 | 3 |
| Not completed | 1 | 3 |
| Withdrew: Disease progression | 1 | 1 |
| Withdrew: Insufficient response | 0 | 2 |
| Milestone | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg Twice Daily (BID) | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID |
|---|---|---|
| Started | 1 | 11 |
| Completed | 1 | 10 |
| Not completed | 0 | 1 |
| Withdrew: Insufficient response | 0 | 1 |
ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0-100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 30 of response, defined as a 30% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%
| participants | Low Dose Discontinued | Low Dose Throughout | Switched Dose | High Dose Throughout | High Dose Discontinued |
|---|---|---|---|---|---|
| ACR Pediatric Response Level 30 | 0 | 1 | 3 | 2 | 1 |
| No response | 1 | 0 | 5 | 0 | 3 |
ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0- 100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 50, 70, 90 and 100 of response, defined as a 50%, 70%, 90% and 100% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%
| participants | Low Dose Discontinued | Low Dose Throughout | Switched Dose | High Dose Throughout | High Dose Discontinued |
|---|---|---|---|---|---|
| ACR Pediatric response Level 50 | 0 | 1 | 1 | 2 | 1 |
| ACR Pediatric response Level 70 | 0 | 1 | 0 | 1 | 0 |
| ACR Pediatric response Level 90 | 0 | 0 | 0 | 0 | 0 |
| ACR Pediatric response Level 100 | 0 | 0 | 0 | 0 | 0 |
Collected over Planned treatment duration was 24 weeks overall (12 weeks + 12 weeks). The mean (SD) duration of treatment was 131.9 (55.9) days overall, with a median duration of 170 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose Discontinued | — | 0/1 (0%) | 1/1 (100%) |
| Low Dose Throughout | — | 0/1 (0%) | 1/1 (100%) |
| Switched Dose | — | 0/8 (0%) | 8/8 (100%) |
| High Dose Throughout | — | 0/2 (0%) | 2/2 (100%) |
| High Dose Discontinued | — | 0/4 (0%) | 4/4 (100%) |
| Event | Low Dose Discontinued | Low Dose Throughout | Switched Dose | High Dose Throughout | High Dose Discontinued |
|---|---|---|---|---|---|
| Abdominal Pain UpperGastrointestinal disorders | 1/1 | 0/1 | 1/8 | 0/2 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 1/1 | 0/1 | 0/8 | 0/2 | 1/4 |
| PharyngitisInfections and infestations | 0/1 | 1/1 | 0/8 | 0/2 | 1/4 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/1 | 0/1 | 0/8 | 0/2 | 0/4 |
| Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders | 1/1 | 0/1 | 0/8 | 0/2 | 0/4 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 1/1 | 0/1 | 0/8 | 0/2 | 0/4 |
| Frequent Bowel MovementsGastrointestinal disorders | 0/1 | 0/1 | 0/8 | 1/2 | 0/4 |
| VomitingGastrointestinal disorders | 0/1 | 0/1 | 1/8 | 1/2 | 1/4 |
| Respiratory Tract InfectionInfections and infestations | 0/1 | 0/1 | 1/8 | 1/2 | 0/4 |
| HeadacheNervous system disorders | 0/1 | 0/1 | 1/8 | 0/2 | 2/4 |
| Age, Continuous(years) | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BID | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID | Total |
|---|---|---|---|
| Mean | 11.7 ± 5.5 | 9.7 ± 5.7 | 10.9 ± 5.4 |
| Sex: Female, Male(Participants) | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BID | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID | Total |
|---|---|---|---|
| Female | 8 | 6 | 14 |
| Male | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BID | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 6 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BID | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID | Total |
|---|---|---|---|
| Serbia | 5 | 1 | 6 |
| Czech Republic | 1 | 1 | 2 |
| Slovenia | 1 | 1 | 2 |
| Romania | 1 | 0 | 1 |
| Italy | 2 | 3 | 5 |
| Body Weight(kg) | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BID | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID | Total |
|---|---|---|---|
| Mean | 37.36 ± 15.40 | 37.92 ± 18.59 | 37.57 ± 16.05 |
| Height(m) | Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BID | High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID | Total |
|---|---|---|---|
| Mean | 1.388 ± 0.204 | 1.365 ± 0.277 | 1.379 ± 0.225 |
The record gives a start of Oct 2010, a primary completion of Jun 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat